Sawai Pharmaceutical Co Ltd - Company Profile
Powered by 
All the data and insights you need on Sawai Pharmaceutical Co Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Sawai Pharmaceutical Co Ltd Strategy Report
- Understand Sawai Pharmaceutical Co Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Sawai Pharmaceutical Co Ltd (Sawai Pharmaceutical) manufactures, sells, imports and exports ethical drugs and proprietary drugs. The company's products include cardiovascular drugs, antihyperlipidemic agents, diabetes drugs, anticancer drugs and OTC drugs. It provides products in the form of tablets, oral dispersing tablets, capsules, granules, injection, tape, ophthalmic and nasal solution and syrup. Sawai Pharmaceutical caters to hospitals, general practitioners and dispensing pharmacies. The company has manufacturing facilities in Kanto, Kashima, Osaka, Daini, Sanda and Kyusyu. It has its presence in Sapporo, Tokyo Daiichi, Sendai, Kitakanto, Tokyo Daini, Nagoya, Osaka, Hiroshima, and Fukuoka. Sawai Pharmaceutical is headquartered in Osaka, Japan.
Headquarters
Japan
Address
5-2-30 Miyahara, Yodogawa-Ku, Osaka, 532-0003
Website
global.sawai.co.jp
Telephone
81 6 6105 5711
No of Employees
2,414
Industry
Pharmaceuticals and Healthcare
Sawai Pharmaceutical Co Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| Product: |
| Cardiovascular Drugs |
| Antihyperlipidemic Agents |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | New Product Approvals | The company announced that, it has received approvals for three generic drugs with ten strengths by the Ministry of Health, Labour and Welfare. |
| 2021 | New Products/Services | In June, the company launched eight generic drugs with 23 strengths leading its product line to comprise of 327 compounds with 808 strengths |
| 2021 | Contracts/Agreements | In January, the company and Neurolief Ltd entered into an exclusive agreement to develop Relivion, a non-invasive digital medical device for migraine and depression, in Japan. |
Competitor Comparison
| Key Parameters | Sawai Pharmaceutical Co Ltd | Chugai Pharmaceutical Co Ltd | COSMOS Pharmaceutical Corp | Sumitomo Pharma Co Ltd | ASKA Pharmaceutical Holdings Co Ltd |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | Japan | Japan | Japan |
| City | Osaka | Chuo-Ku | Fukuoka City | Osaka-Shi | Minato-Ku |
| State/Province | Osaka | Tokyo | Fukuoka | Osaka | Tokyo |
| No. of Employees | 2,414 | 7,771 | 5,290 | 6,250 | 747 |
| Entity Type | Private | Public | Public | Public | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Mitsuo Sawai | Chairman - Group; Chief Executive Officer; Representative Director | Executive Board | 2021 | 68 |
| Kazuhiko Sueyoshi | President; Supervisor of Corporate Strategy | Executive Board | 2021 | 64 |
| Motohiko Kimura | Director; President | Executive Board | - | - |
| Toru Terashima | Group Chief Quality & Safety Officer; Director | Executive Board | 2021 | 65 |
| Taku Nakaoka | Group Chief Strategy Officer | Senior Management | 2021 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward